Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Evidence for the efficacy of aztreonam for inhalation solution in the management of Pseudomonas aeruginosa in patients with cystic fibrosis

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Predictors for antibiotic prescribing in patients with exacerbations of COPD in general practice

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Cystic fibrosis newborn screening in Denmark: Experience from the first 2 years

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Markers of bone turnover are reduced in patients with CF related diabetes; the role of glucose

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Optimization of colistin dosing regimen for cystic fibrosis patients with chronic Pseudomonas aeruginosa biofilm lung infections

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Antibody response against Mycobacterium avium complex in cystic fibrosis patients measured by a novel IgG ELISA test

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Cystic fibrosis - an example of personalized and precision medicine

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

Vis graf over relationer

Chronic airway infection in cystic fibrosis (CF) is a main cause of the increased morbidity and mortality found with this disease. The most common cause of Gram-negative infection is Pseudomonas aeruginosa. The introduction of inhaled antibiotics has changed the lives of affected patients and the clinical outcome of this infection; this article focuses on the use of inhaled antibiotics in chronic P. aeruginosa infection in CF, and specifically on studies including the use of inhaled aztreonam lysine in P. aeruginosa infection. Studies were identified using PubMed and ClinicalTrials.gov, searching for 'inhaled aztreonam' and 'cystic fibrosis'. Inhaled aztreonam is an important new treatment option for chronic P. aeruginosa infection in CF. Long-term studies have shown that the drug is safe and superior to inhaled tobramycin in these specific infections.

OriginalsprogEngelsk
TidsskriftTherapeutic Advances in Respiratory Disease
Vol/bind9
Udgave nummer1
Sider (fra-til)16-21
ISSN1753-4658
DOI
StatusUdgivet - 2015

ID: 45094761